We serve Chemical Name:1-methylsulfonyl-2,3-dihydroindol-5-amine CAS:299921-01-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-methylsulfonyl-2,3-dihydroindol-5-amine
CAS.NO:299921-01-0
Synonyms:1-Methanesulfonyl-2,3-dihydro-1H-indol-5-ylamine
Molecular Formula:C9H12N2O2S
Molecular Weight:212.26900
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:71.78000
Exact Mass:212.06200
LogP:2.31790
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-Methanesulfonyl-2,3-dihydro-1H-indol-5-ylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methanesulfonyl-2,3-dihydro-1H-indol-5-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methanesulfonyl-2,3-dihydro-1H-indol-5-ylamine Use and application,1-Methanesulfonyl-2,3-dihydro-1H-indol-5-ylamine technical grade,usp/ep/jp grade.
Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 1-methylsulfonyl-2,3-dihydroindol-5-amine manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 1-methylsulfonyl-2,3-dihydroindol-5-amine supplier Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. 1-methylsulfonyl-2,3-dihydroindol-5-amine vendor As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 1-methylsulfonyl-2,3-dihydroindol-5-amine factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.
